We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.84%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.85B
AUM Growth
+$135M
Cap. Flow
-$194M
Cap. Flow %
-10.46%
Top 10 Hldgs %
58.55%
Holding
374
New
79
Increased
68
Reduced
92
Closed
116

Top Buys

Rank Stock Value
1
BIOA
BioAmber Inc.
BIOA
+$5.55M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.2M
3
OTIC
Otonomy, Inc.
OTIC
+$3.92M
4
BLRX
BioLineRX
BLRX
+$3.37M
5
SLS icon
SELLAS Life Sciences
SLS
+$2.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$62.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$59.7M
3
AMGN icon
Amgen
AMGN
+$35.8M
4
LLY icon
Eli Lilly
LLY
+$15.7M
5
BIIB icon
Biogen
BIIB
+$5.67M

Sector Composition

Rank Sector Weight
1 Miscellaneous 92.69%
2 Healthcare 6.69%
3 Materials 0.25%
4 Financials 0.16%
5 Technology 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACOR
201
CALL
DELISTED
Acorda Therapeutics
ACOR
$313K 0.02%
1
-2
-67% -$5.76K
MNKD icon
202
MannKind Corp
MNKD
$1.14B
$310K 0.02%
+209,292
New +$549K
TENX icon
203
Tenax Therapeutics
TENX
$68.5M
$300K 0.02%
36
-11
-23% -$400K
BCLI
204
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$296K 0.02%
4,636
-12,082
-72% -$629K
SGMO
205
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$289K 0.02%
+556
New +$2.23K
NSPRW
206
DELISTED
InspireMD, Inc. Warrants
NSPRW
$258K 0.01%
1,214,925
+4,819
+0.4% +$2.02K
ITCI
207
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$257K 0.01%
158
-1,623
-91% -$23.5K
SIOX
208
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$250K 0.01%
2,089
-10,536
-83% -$1.1M
SGLBW
209
DELISTED
Sigma Labs, Inc. Warrant
SGLBW
$250K 0.01%
+250,000
New +$272K
AMAG
210
CALL
DELISTED
AMAG Pharmaceuticals
AMAG
$246K 0.01%
+109
New +$2.61K
XLRN
211
CALL
DELISTED
Acceleron Pharma
XLRN
$244K 0.01%
+92
New +$2.42K
SAGE
212
DELISTED
Sage Therapeutics
SAGE
$240K 0.01%
+3,379
New +$198K
NSPR icon
213
InspireMD
NSPR
$36.1M
$237K 0.01%
+9
New +$480K
CSBR icon
214
Champions Oncology
CSBR
$66.4M
$227K 0.01%
71,700
-181,804
-72% -$636K
ADXS
215
CALL
DELISTED
Advaxis Inc
ADXS
$221K 0.01%
18
– –
RCKT icon
216
Rocket Pharmaceuticals
RCKT
$374M
$202K 0.01%
25,233
-12,500
-33% -$84.1K
GALT icon
217
PUT
Galectin Therapeutics
GALT
$376M
$193K 0.01%
840
+605
+257% +$912
NURO
218
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$187K 0.01%
472
+212
+82% +$91.5K
PARN
219
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$181K 0.01%
203,549
+3,000
+1% +$2.67K
TXMD icon
220
CALL
TherapeuticsMD
TXMD
$25M
$180K 0.01%
5
-9
-64% -$2.79K
FOMX
221
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$173K 0.01%
35,037
-23,301
-40% -$224K
ENLV icon
222
Enlivex Ltd
ENLV
$15.4M
$167K 0.01%
367
-733
-67% -$483K
MNKD icon
223
CALL
MannKind Corp
MNKD
$1.14B
$167K 0.01%
+1,127
New +$2.96K
SLNO
224
DELISTED
Soleno Therapeutics
SLNO
$159K 0.01%
3,119
+732
+31% +$43.2K
OTIC
225
PUT
DELISTED
Otonomy, Inc.
OTIC
$159K 0.01%
+130
New +$1.89K
7 8
9
10 11

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sabby Management held 374 positions worth $1.85B, up 7.8% from $1.72B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sabby Management withdrew a net $194M in Q1 2017, closing 116 positions and reducing 92 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $62.4M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 93% of assets, up from 81% a quarter earlier, followed by Healthcare and Materials.

Against the trend, Sabby Management opened a new position in BioAmber Inc. worth $3.39M.

  • Sabby Management's largest Q1 2017 buy was BioAmber Inc.: 1,460,859 shares worth $3.39M.
  • Sabby Management added most to Otonomy, Inc. in Q1 2017, an estimated $3.92M increase.
  • Sabby Management's biggest Q1 2017 reduction was Amgen, cutting an estimated $35.8M.
  • Sabby Management fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $62.4M.
  • Sabby Management's ten largest holdings make up 59% of its $1.85B portfolio in Q1 2017.
  • Sabby Management opened 79 new positions and closed 116 in Q1 2017.
  • Sabby Management's portfolio value rose 7.8% quarter-over-quarter to $1.85B.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.